Purpose: To describe level of function, psychotic and psychiatric symptoms in a 10-year follow up of individuals with autism and psychotic symptoms. Method: A case-control study based on a cohort of 48 teenagers with autism established 2013. In the original study, 22 participant reported psychotic symptom in self-evaluation questionnaires design for early detection. We aim to recruit these individuals and controls from the same cohort without psychotic symptoms. Data will be collected from self-rating scales, clinical evaluation including semi-structured interviews and healthcare journals. The study is primarily descriptive, with group comparison by non-parametric method.
Design: Case-control study. Participants: Participants will be recruited from a previous study cohort established in Region Varmland in 2013, comprising 48 adolescents diagnosed with autism. Psychotic symptoms were identified through self-report in 22 participants. These individuals will be re recruited, along with controls from the same cohort with autism but no psychotic symptoms. In the original study, participants were 15-18 years old at the time of screening, had a diagnosis of autism spectrum disorder (including Asperger's syndrome), and an IQ ≥ 70. Instruments: Youth Psychosis at Risk Questionnaire - Brief Version (YPARQ B). A shortened version of the Youth Psychosis at Risk Questionnaire developed to capture early psychotic symptoms. Prodromal Questionnaire - Brief Version (PQ B): Self report scale assessing psychotic symptoms, including associated distress. Montgomery-Åsberg Depression Rating Scale - Self Report (MADRS S): Swedish self report scale for depressive symptoms. Self evaluation of Negative Symptoms (SNS): Instrument for assessing negative symptoms in psychotic disorders; Swedish translation available. Positive and Negative Syndrome Scale (PANSS): Structured clinical interview assessing positive and negative psychotic symptoms; validated and translated into Swedish. Structured Clinical Interview for DSM 5, Clinician Version (SCID 5 CV): Semi structured diagnostic interview. Mini International Neuropsychiatric Interview (MINI): Structured diagnostic interview. Clinical Global Impression - Severity (CGI S): Clinician rated scale for assessing severity of psychiatric illness. Personal and Social Performance Scale (PSP): Clinician rated measure of global functioning in psychotic disorders. Procedure: Approximately ten years after the initial study recruitment, participants will complete PQ B, YPARQ B, SNS, and MADRS-S. Current psychotic symptoms and psychiatric comorbidity will be assessed in clinical evaluation, including PANSS, the psychosis module of SCID 5 CV, and MINI. Socioeconomic status will be assessed. Functional level will be rated using CGI-S and PSP. With participant consent, information regarding psychiatric diagnoses and current pharmacological treatment will be requested from healthcare region. Analysis: Group comparisons will be conducted using non parametric methods. A roughly 1:1 ratio between case and control groups is expected.
Study Type
OBSERVATIONAL
Enrollment
48
None. Observational study.
Number of participants with psychotic disease
Time frame: Single time point at enrollment
Number of participants with non-psychotic psychiatric disease
Time frame: Single time point at enrollment
Number of participants with psychotic symptoms without psychotic disease
Time frame: Single time point at enrollment
Number of participants with functional impairment
Time frame: Single time point at enrollment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.